ALGN vs GSK
Align Technology vs GSK plc — AI-powered side-by-side comparison
ALGN
Align Technology
73
Buy
VS
GSK
GSK plc
64
Insufficient Data
| Metric | ALGN | GSK |
|---|
| AI Score |
73
|
64
|
| Price |
$172.86
|
$50.91
|
| P/E Ratio |
30.03×
|
15.80×
|
| ROE |
10.1%
|
35.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.5%
|
73.3%
|
| Debt / Equity |
0.03×
|
1.03×
|
| Dividend Yield |
0.0%
|
3.5%
|
| RSI (14) |
55.1
|
39.2
|
| Beta |
1.653
|
0.3
|
| Expected Upside |
+7.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALGN versus GSK.
ALGN leads by 9 points.
ALGN scores 73/100 (Buy) versus GSK at 64/100 (Insufficient Data).
ALGN Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
GSK Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.27 across 20 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical